2207: A Phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer

OBJECTIVES/SPECIFIC AIMS: Patients with locally advanced pancreatic cancer typically have poor outcomes, with a median survival of ~16 months. Novel methods to improve local control are needed. Nab-paclitaxel (abraxane) has shown efficacy in pancreatic cancer and is FDA approved for metastatic disea...

Descripción completa

Detalles Bibliográficos
Autores principales: Ezra Shabason, Jacob, Chen, Jerry, Apisarnthanarax, Smith, Damjanov, Nevena, Giantonio, Bruce, Loaiza-Bonilla, Arturo, O’Dwyer, Peter, O’Hara, Mark, Reiss, Kim, Teitelbaum, Ursina, Wissel, Paul, Drebin, Jeffery, Vollmer, Charles, Kochman, Michael, Mick, Rosemarie, Vergara, Norge, Jhala, Nirag, Berman, Abigail, Dorsey, Jay, Evans, Sydney M., Kao, Gary, Lukens, John N., Plastaras, John P., Metz, James M., Ben-Josef, Edgar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2018
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798698/
http://dx.doi.org/10.1017/cts.2017.121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798698/
http://dx.doi.org/10.1017/cts.2017.121

Ejemplares similares